InvestorsHub Logo
Followers 52
Posts 9089
Boards Moderated 1
Alias Born 10/25/2007

Re: None

Monday, 08/28/2023 11:56:11 PM

Monday, August 28, 2023 11:56:11 PM

Post# of 13461
CARsgen and Moderna have initiated a collaboration agreement to investigate CT041 in combination with Moderna's investigational Claudin18.2 mRNA cancer vaccine.

Business Highlights

Collaboration agreement for zevor-cel commercialization in mainland China with Huadong Medicine.
CT041 has achieved IND clearance from the NMPA for the postoperative adjuvant therapy of Claudin18.2 positive pancreatic cancer (PC).
CT041 Phase 2 clinical trial has been initiated in the U.S. for the treatment of Claudin18.2 positive advanced gastric cancer/gastroesophageal junction cancer (GC/GEJ) in patients who have failed at least 2 prior lines of systemic therapies.

https://www.nasdaq.com/press-release/carsgen-announced-2023-interim-results-2023-08-22
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent MRNA News